Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 3/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27028537 | 0.89 | ADORA2B (0.36) | ADORA2BGLSKDM4EALDH1A1GLA | |
| SCHEMBL27200017 | 0.82 | KCNJ6 (0.34) | GLS | |
| SCHEMBL27028481 | 0.82 | GAA (0.34) | GAAGLSKMT2AALDH1A1MAPT | |
| SCHEMBL27200014 | 0.82 | HPGD (0.34) | GAAGLSMEN1KMT2AMAPT | |
| SCHEMBL27200051 | 0.81 | CRHR1 (0.35) | GLSALDH1A1MAPT | |
| SCHEMBL27200041 | 0.81 | GLS (0.31) | GLS | |
| SCHEMBL27200031 | 0.80 | MAP3K14 (0.35) | ADORA2BGAAGLSKDM4EMAPT | |
| SCHEMBL27200057 | 0.79 | STIM1 (0.37) | — | |
| SCHEMBL27200074 | 0.79 | KDM4E (0.31) | KDM4E | |
| SCHEMBL27028503 | 0.75 | S1PR1 (0.39) | ADORA2BS1PR1GAAKRASGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383903-A1 | Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-11964978-B2 | Modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4308563-A1 | MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | Pfizer Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117321055-A | Modulators of STING (interferon gene stimulators) | 辉瑞公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20220306641-A1 | Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2022-09-29 | — | — | US | disclosed |
| WO-2022195462-A1 | MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964978-B2 | Modulators of STING (stimulator of interferon genes) | STING1, IRF3, CGAS | ADORA2B 1784/4885S1PR1 2542/4885GAA 372/4885 |
| US-20220306641-A1 | Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | ADORA2B 1784/4885S1PR1 2542/4885GAA 372/4885 |
| US-20240383903-A1 | Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | ADORA2B 1784/4885S1PR1 2542/4885GAA 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.